Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
← catalyst calendarNCT07287189 · readout in 224 d
Sponsored by Satellos Bioscience, Inc. (industry) · MSLE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
51estimated
Sites
21
Countries
Australia, Belgium, Canada +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-08 | actual | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Duchenne Muscular Dystrophy
- Duchenne
- DMD
- Neuromuscular Diseases
- Muscular Dystrophies
Interventions
- Drug: SAT-3247
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFSafety of SAT-3247
measured 12 weeks in Part 1 and up to 12 months in part 2
Tolerability of SAT-3247
measured 12 weeks in Part 1 and up to 12 months in Part 2
SAT-3247 effects on muscle strength
measured 12 weeks in Part 1 and up to 12 months in Part 2
Permalink · MSLE's whole pipeline · Catalyst calendar · Every registered study · What changed